Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio intervencionista sobre la reducción del tabaquismo en la psiquiatría (TABAPSY)

7 de octubre de 2026 actualizado por: GCS-CCOMS

Evaluación de una intervención para reducir el tabaquismo entre los usuarios de salud mental tratados en psiquiatría ambulatoria

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.

The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.

While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.

Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:

  1. A general information meeting, to encourage motivation to start smoking cessation;
  2. An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
  3. Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
  4. Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.

The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.

A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).

It will be supplemented by a qualitative study to study the implementation of the intervention.

All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.

6,250 participants will be included over 12 months, in 22 participating sectors.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

6500

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Armentières, Francia, 59280
        • Terminado
        • Public mental health establishment of Lille Metropole (59G16-G17)
      • Armentières, Francia, 59280
        • Terminado
        • Public mental health establishment of Lille Metropole (59G21)
      • Bailleul, Francia, 59270
        • Terminado
        • Flanders public mental health establishment (59G05/06)
      • Laxou, Francia, 54520
        • Terminado
        • Psychotherapeutic center of Nancy (54G02-06)
      • Lille, Francia, 59000
        • Retirado
        • University Hospital Center of Lille (59G08)
      • Nanterre, Francia, 92014
        • Terminado
        • Hospital Care Center of Nanterre (92G10)
      • Paris, Francia, 75014
        • Terminado
        • University Hospital Group Paris Neurosciences & Psychiatry (75G04)
      • Rouffach, Francia, 68250
        • Terminado
        • Hospital Center of Rouffach (68G02/03)
      • Rouffach, Francia, 68250
        • Terminado
        • Hospital Center of Rouffach (68G08/09)
      • Rouffach, Francia, 68250
        • Terminado
        • Hospital Center of Rouffach (Pôle LTD - 68G04/05)
      • Saint-Maurice, Francia, 94410
        • Terminado
        • Hospitals of Paris Est Val de Marne (94G01)
      • Saint-Maurice, Francia, 94410
        • Terminado
        • Hospitals of Paris Est Val de Marne (94G16)
      • Saint-Maurice, Francia, 94410
        • Terminado
        • Hospitals of Paris Est Val de Marne (Paris 11)
      • Saint-Maurice, Francia, 94410
        • Terminado
        • Hospitals of Paris Est Val de Marne (Paris 12)
      • Saint-Maurice, Francia, 94410
        • Terminado
        • Hospitals of Paris Est Val de Marne (Paris Centre)
      • Saint-Venant, Francia, 62350
        • Terminado
        • Public mental health establishment of Val de Lys Artois (62G09)
      • Saint-Venant, Francia, 62350
        • Terminado
        • Public mental health establishment of Val de Lys Artois (62G12)
      • Saint-Venant, Francia, 62350
        • Terminado
        • Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
      • Étampes, Francia, 91150
        • Reclutamiento
        • Barthelemy Durand public health establishment (91G05)
        • Contacto:
        • Investigador principal:
          • Amina AMRANDI, MD
      • Saint-Claude, Guadalupe, 97122
        • Reclutamiento
        • Public mental health establishment of Guadeloupe (96G06)
        • Contacto:
        • Investigador principal:
          • Isabelle DELAROZIERE, MD
      • Saint-Claude, Guadalupe, 97122
        • Reclutamiento
        • Public mental health establishment of Guadeloupe (96G01)
        • Contacto:
        • Investigador principal:
          • Magloire MPEMBI, MD
      • Saint-Paul, Reunión, 97460
        • Terminado
        • Public mental health establishment of Reunion Island (Pôle Nord)

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Regular smokers (at least one cigarette per day)
  • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
  • Adults (18 years or older)
  • Covered by the statuary health insurance
  • Who gave their informed consent to participate to the study

Exclusion Criteria:

  • Users under guardianship or legal protection,
  • Psychological state incompatible with completing the questionnaire,
  • Persons with no command or understanding of the French language

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention arm

Sectors randomized to the intervention group will implement the 'Tabapsy' intervention.

The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.

The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur

Otro: Usual care

Sectors randomized to the control group will continue implementing their usual smoking cessation promotion.

Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Short-term smoking cessation
Periodo de tiempo: 3 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Motivation to stop smoking
Periodo de tiempo: 3 and 6 months

The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation.

3 and 6 months
Voluntary quit attempts lasting at least 24 hours in the last 3 months
Periodo de tiempo: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use

3 and 6 months
Voluntary quit attempts lasting at least 7 days in the last 3 months
Periodo de tiempo: 3 and 6 months

Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user.

3 and 6 months
Tobacco consumption
Periodo de tiempo: 3 and 6 months

Number of cigarettes smoked per day

3 and 6 months
Nicotine dependence
Periodo de tiempo: 3 and 6 months

Nicotine dependence will be measured by the 6-question Fagerström test.

3 and 6 months
Short-term smoking cessation
Periodo de tiempo: 6 months

Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study.

6 months
Medium-term smoking cessation
Periodo de tiempo: At 3 and 6 months

Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study.

At 3 and 6 months
Use of smoking cessation aids
Periodo de tiempo: 3 and 6 months

Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately

3 and 6 months
Level of mental well-being
Periodo de tiempo: 3 and 6 months

Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being

3 and 6 months
Level of physical well-being
Periodo de tiempo: 3 and 6 months

Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being

3 and 6 months
Knowledge and representations surrounding tobacco use
Periodo de tiempo: 3 and 6 months

Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop

3 and 6 months
Cost-effectiveness (short-term)
Periodo de tiempo: A 6 months

Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days.

A 6 months
Cost-effectiveness (long-term)
Periodo de tiempo: 6 months

Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased.

6 months
Budgetary impact (costs)
Periodo de tiempo: 5 years after hypothetical generalization

Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization.

5 years after hypothetical generalization
Budgetary impact (health benefits)
Periodo de tiempo: 5 years after hypothetical generalization

The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization.

5 years after hypothetical generalization
Implementation
Periodo de tiempo: 6 months

The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group).

6 months
Satisfaction level
Periodo de tiempo: 3 and 6 months

Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction.

3 and 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Jean-Luc ROELANDT, MD, GCS-CCOMS & INSERM ECEVE 1123
  • Director de estudio: Karine CHEVREUL, MD and Pr of public health, Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de enero de 2025

Finalización primaria (Actual)

15 de julio de 2026

Finalización del estudio (Estimado)

14 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

18 de febrero de 2025

Primero enviado que cumplió con los criterios de control de calidad

7 de abril de 2025

Publicado por primera vez (Actual)

13 de abril de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

7 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2024-A01474-43
  • A19017HS (Otro identificador: Institute for Public Health Research (IRESP))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir